Skip to main content

BRIEF RESEARCH REPORT article

Front. Public Health
Sec. Public Health Policy
Volume 12 - 2024 | doi: 10.3389/fpubh.2024.1392996

Trends of 2 nd Measles Vaccine (MCV2) over time after its launch as part of Routine Immunization (RI) in Nigeria: Brief Research Report

Provisionally accepted
Ryoko Sato Ryoko Sato *
  • Other, Boston, United States

The final, formatted version of the article will be published soon.

    Nigeria has one of the highest measles burdens and lowest vaccination coverage in the world. Geographical disparity in the coverage has also been persistent. Between 2019 and 2021, the Nigerian government introduced the 2nd dose of measles-containing vaccine (MCV2) with into the routine immunization (RI). This study evaluated the trends of the MCV2 coverage over time across geographical zones. The monthly data on the MCV2 coverage from District health Information Software (DHIS2) for all the health facilities in Nigeria were aggregated by the geopolitical zone and the trend of the MCV2 coverage was analyzed over time. The MCV2 coverage in each zone was approximately 20% when MCV2 program was launched. One year after the launch (year 1), the MCV2 coverage was higher in northern zones (35 to 42%) compared with southern zones (22 to 31%). Similarly at year 2.5, the MCV2 coverage was 38 to 46% in northern zones while it was 23 to 37% in southern zones. The introduction of MCV2 as part of RI schedule potentially narrows down the health inequity in Nigeria.

    Keywords: Measles, measles containing vaccine, MCV, Routine immunization, Nigeria

    Received: 28 Feb 2024; Accepted: 10 Oct 2024.

    Copyright: © 2024 Sato. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Ryoko Sato, Other, Boston, United States

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.